key: cord-1044128-v26ocnwg authors: Hebbani, Ananda Vardhan; Pulakuntla, Swetha; Pannuru, Padmavathi; Aramgam, Sreelatha; Badri, Kameswara Rao; Reddy, Vaddi Damodara title: COVID-19: comprehensive review on mutations and current vaccines date: 2021-12-06 journal: Arch Microbiol DOI: 10.1007/s00203-021-02606-x sha: 1805b3a7b89e65bee17943d986bae05e84a9b7c9 doc_id: 1044128 cord_uid: v26ocnwg Viral outbreaks had been a threat for the human race for a long time. Several epidemics and pandemics have been reported in the past with serious consequences on human health and subsequent social and economic aspects. According to WHO, viral infections continue to be a major health concern globally. Novel coronavirus, SARS-CoV-2 (Severe acute respiratory syndrome coronavirus-2) causes the most recent infectious pandemic disease, COVID-19 (Coronavirus disease-19). As of now, there were 249 million infections of COVID-19 worldwide with a high mortality of more than 5 million deaths reported; and the number of new additional cases is drastically increasing. Development of therapies to treat the infected cases and prophylactic agents including vaccines that are effective towards different variants are crucial to curtail the COVID-19 pandemic. Owing to the fact that there is a high mortality and morbidity rate along with the risk of virus causing further epidemic outbursts, development of additional effective therapeutic and preventive strategies are highly warranted. Prevention, early detection and treatment will reduce the spread of COVID-19 pandemic. The present review highlights the novel mutations and therapeutic updates associated with coronaviruses along with the clinical manifestations—diagnosis, clinical management and, prophylactic and therapeutic strategies of COVID-19 infection. An incidence of unidentified pneumonia caused by 2019-nCoV/SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronovirus-2) was reported in the Wuhan city, China in the final months of 2019 . The unidentified pneumonia was termed as considered to have spread from bats to humans. The mode of spreading from human to human is predominantly, through airborne respiratory droplet contact. The basic reproduction number (R 0 ) of the virus is analyzed to be in between 1.4 and 6.47 across different countries, which is not just of wider range when compared to the other corona viral infections, but also stands at a position very near after the other well-known infectious diseases such as Measles, Chickenpox, Mumps, Polio and Rubella Tang et al. 2020) . Genetic and phylogenetic analysis revealed that SARS-CoV-2 belongs to β-coronaviruses along with the other two predominant members, i.e., MERS-CoV (Middle East respiratory syndrome-related coronavirus) and SARS-CoV (severe acute respiratory syndrome coronavirus) (Leao et al. 2020 According to the Coronaviridae study group of Animal ssRNA + viruses subcommittee of the ICTV (International Virus Taxonomy committee), Coronaviridae is the largest family of Coronaviruses (CoVs) belongs to the suborder Cornidovirineae, order Nidovirales, phylum Incertae sedis and realm Riboviria. The Coronaviridae family has 2 subfamilies, 5 genera, 27 subgenera and 46 species, based on serologic and genetic analysis (de Groot et al. 2013; Pascarella et al. 2020) .The detailed genetic lineages are presented in Figs. 1 and 2. There are similarities either in the perspective of disease caused or viral receptor type/distribution amongst the human coronaviruses and the details are summarized in Table 1 . CoVs are roughly spherical, moderately pleomorphic and a typical virion has been reported to be of an average diameter of 80-125 nm, enveloped, with single stranded positive (-sense) RNA viruses with a nucleocapsid. The RNA genome is of 26-32 kb in size with 7-10 translatable ORFs (open reading frames). ORF1a and b are translated into proteins, pp1a and pp1ab (polyprotein 1a and 1ab). These polyproteins will be processed by viral proteases to synthesize 16 non-structural proteins. Among those, RNA-dependent RNA-polymerase enzyme (RdRp) is one that aids in replicating viral RNA through transcription of a minus strand template, during which CoVs generate 6 to 9 sub-genomic mRNAs (sgmRNAs) that help in translation of the accessory and structural proteins from the downstream ORFs. Viral genome also codes for all the necessary viral structural and functional proteins (viral infection and replication) including envelope protein (E), nucleocapsid protein (N), membrane protein (M) and spike protein (S) (Ahn et al. 2020 ). We have reported different global mutations of SARS-CoV-2 presented globally during Dec 2019 to June 2021. This data were collected from multiple resources including Table 2 . Non-structural proteins of the coronavirus wholegenome encodes 6 ORFs, the largest occupied by ORF1ab polyproteins which can produce the 16 non-structural proteins (nsps) that are important for the viral replications. NSPs has the highest number of missense mutations in the ORF1ab region found in 1905 mutations. Out of total mutations 3328, 1344 are synonymous mutations 57 are deletion mutations, 2 are insertion mutations, 7 are frame shift deletion mutations, and 13 are stop-gained (Koyama et al. 2020) . The most frequent mutations E191G, G76S, K61N, V259L, T176I, L140V, T269M and V88L are in the ORF region. We have reported multiple mutations in nsp, RdRp including P323L and 11 deletions in the conserved region that may be useful for the drug target for antiviral drugs . India D614G, P323L, G1124V, R203K and G204R, Q271R, R78M, E583D, L54F, K77M, A520S, A706S, G1251V, T22I, E471Q, S494P, G1124V, Q271R, L5F, F2L, G261S,M177I, L7I, E156D, S162I, T572I, Q6771H, L18F, E224G, A243S, T299I, P82L, D290Y, K558N, D574H, R634S, I402L, Y28H, T274I, T323I, T1027I, H49Y, T602I, A879S, V1104L, P1263L, M731R, F797C, T761S, L828P, A831S, G857C, A930T, H1101Y, K1191N, A771V,T1027I, C1243F, G769V, C1250F, G125V, Synomous:L84S, D614G, G251V, P214L, R203K, G204R, Q57H, N679Y, S680P, Q677H, Q675H, T175M and D3G Synonymous: D467V, I468F, I468T, I472V, G476S, S477G, V483A, P491R, Y508H, R509K and V510L Kim et al. (2020) Multiple countries L54F, A27V, T29I, H49I, H49Y, E96D, D111N, T240I, G176V, A348T, G476S, V483A, A520S, H519Q, D614G, D936Y, A1078V and D1259H, F106F, P314L, Q57H, G203K&R, T85I,L37F, Y446Y, G251V, S76S, L84S, L7L, M54K, P504L, P585S, I559V, R337R, D268*, G212D,S247R, V378I, L84S, G392D, A376T, P334S, L3606F, G251V Mercatelli and Giorgi (2020) India T19R, K77T, T95I, G142D, E154K, N440K, L452R, T478K, E484Q, D614G, P681R, D950N, Q1071H, H1101D Cherian et al. (2021) China F2L, Q14S, V16L, T29S, K41T, V42I, S46N T51S, D53G, F59Y, I62L, S65N, F73V, N81K, V84I, S91A, I101V, T114S, V127I, E132N, F140Y, Q173K L176M, M177L, L179M, Q183S, K187D, N188T, I210V, N211D, L212V, D215N, D228E, L229I, R237K, Q239R, A243T, L244I The spike (S) region is a large multifunctional and transmembrane protein. In spike protein, the receptor-binding domain (rbd) has an affinity to bind with ACE2 (Angiotensin-converting enzyme 2) of the host cells and facilitates the corona viral entry into the host cell, leading to the rapid transmission for the infection of the SARS-CoV-2. Comparison of various global strains with Wuhan sequence revealed 394 missense mutations, 260 synonymous, 5 deletions 1framshift and 1 stop-gained 6 overall all mutations in spike region 687 ). Among the two sub-regions of spike protein, S1 and S2 domain, the S1 domain having the highest number of mutations D614G, Y28H, H49Y, R78M, K77M, Q271R, T22I G261S, E471, S494, A520S and I402L responsible for the pathogenicity of the SARS-CoV-2 (Maitra et al. 2020; Pulakuntla et al. 2021) . Our studies also identified high-frequency combination mutations like D614G + I472V, D614G + K458R, D614G + V341I, D614G + Q675H, D614G + Q675H, D614G + S939F, D614G + D936Y and D614G + L5F are responsible for increased infectivity ). This may potentially reorganize S protein with loss of hydrogen bonds with adjacent residues there by enhancing binding of S1 region with ACE2 enhancing viral entry and host to host transmission. These mutations and these areas of spike protein must be investigated. The D614G is a strong non-synonymous mutation along with these few other frequent mutations in the S region including L84S, D614G, G251V, P214L, R203K, G204R, Q57H, N679Y, S680P, Q677H, Q675H, T175M and D3G. Out of these 11 mutations, V510L, R509K, Y508H, P491R, V483A, S477G, G476S, I472V, I468T, I468F and D467V are synonymous and located near to ACE2 receptor binding site (Pulakuntla et al. 2021) . The association of V483H and G476S mutations on human ACE2 receptor binding capacity in MERS and SARS research have been demonstrated (Cherian et al. 2021) . Novel mutations of SARS-CoV-2 started showing up leading to the second wave of infections during December 2020 to March 2021. Among these most frequent triple mutations are T19R, K77T, T95I, G142D, E154K, N440K, T478K, E484Q, D614G, P681R, D950N, Q1071H and H1101D (Cherian et al. 2021) . Aforementioned D614G mutations are generally associated with B.1 lineage of viruses, which has many sublineages and all of them are established to show multiple changes in spike proteins. The sublineage B.1.617.2 lineage is referred to as SARS-CoV-2 Delta variant, which has been the latest mutational variant observed globally (Planas et al. 2021 ). There are multiple SARS-CoV-2 variants that include Alpha (B. and P.1. P.1.1, P.1.2 (gamma) were categorized initially as variants of concern based on increases transmissibility and increased disease severity and evidence of impact on diagnosis, treatment and protectiveness against vaccines. Even though, Alpha, Beta, Gamma and Epsilon variants were categorized variants of concern until recently, but now they were categorized as variants being monitored (VM SARS-CoV-2 B.1.617.2 also termed as delta variant was reported to have got identified in October 2020 predominantly in India and further supposed to have spread to the UK and many other countries by December 2020. SARS-CoV-2 Delta variant is one among the three major subtypes viz., B1.617.1, B1.617.2 and B1.617.3 which contain mutations predominantly in the N-terminal and the receptor binding domains of S-proteins. Since mutations are associated with S-protein (T19R, V70F*, T95I, F142D, E156-, F157-, R158G, A222V*, W258L*, K417N*, L452R, T478K, D614G, P681R, D950N) in delta variant is understood to be much more infectious with very fast rate of infectivity when compared to other variants. Thus, SARS-CoV-2 Delta variant is being classified as variant of concern (VOC) by Centres for Disease Control and Prevention (CDC), USA; with enhanced (> 60%) transmissibility potential in comparison to the other variants (Planas et al. 2021) . Corona envelope protein is the smallest and important structural protein key in the assembly and budding of the virus. Deletion of E-protein led to attenuated virus production. The 8 Page 6 of 17 membrane peptide works as a viroporin and inactivation or lack of this protein, the structural changes can take place in the virus leading to transmission. It has three domains, C-terminal domain (functional), amino-terminal (hydrophobic) and transmembrane domain (hydrophobic). The E-protein of SARS-CoV-2 is being considered as one of the highly conserved proteins. E protein has a limited number of mutations while comparing with other proteins and about 43 synonymous and missense mutations were reported (Koyama et al. 2020) . Studies showed that enhanced amino acid variations were observed in the C-terminal domain of the E protein that were playing a key role in COVID-19 pathogenesis (Rahman et al. 2021) . Transmembrane domain mutation (V25A) and many triple cysteine motif harbouring mutations (L39M, A41S, A41V, C43F, C43R, C43S, C44Y and N45R) are being reported as the major variants of E protein mutations, which control conformational and binding characteristics of E-protein (Rahman et al. 2021) . Though highly conserved, the observed mutations in E protein have got a lot of biological relevance and importance, especially to design a therapeutic intervention. Membrane viral protein of the coronavirus is the most abundant envelope protein of coronaviruses. M-Protein play a key role in viral assembly, morphogenesis and antigenecity. It shapes the envelope and it could bind with nucleocapsid and be involved in coronavirus assembly. It has three transmembrane domains, with an amino terminus (short) that projects out and c-terminus (long) that projects inside of the virus. In silico studies reported that the M-protein of SARS-CoV-2 is > 98% similar to that of bat and pangolin SARS-CoV, which demonstrates its evolutionarily conserved nature (Thomas 2020) . Though relatively uncommon, M protein gene mutations are being newly observed especially in the USA patient pool, which is reported to be the reason behind the hike in the number of COVID positive cases (Shen et al. 2021 ). Emergence of novel M182T and V70L are being reported across the globe and the present evidence suggests that so far 71 synonymous mutations associated with M gene are being identified (Koyama et al. 2020) . Mutations associated with M proteins seem to be more alarming because of the observation that the average age of the patient pool associated with M mutation is 4.6-6.3 years (Shen et al. 2021 ). The nucleocapsid protein is multifunctional majorly facilitates genome packing and assembles the viral RNA with membrane proteins. It can enhance the transcription efficiency of the virus. N protein has conserved N-terminal and C-terminal domains. N-protein also modulates the antiviral function as an antagonist to interferon the host response. N protein of SARS-CoV showed frequent mutations, P46S, S194L, K247I, S327L, D343V and E378Q. Koyama et al. (2020) reported a total of 378 mutations out of which 246 are missense mutations, 126 are synonymous mutations and 6 deletion mutations viz., ORF3a, ORF6, ORF7, ORF8 and ORF10 of the viral genome have relatively fewer mutations, i.e., 344 missense mutations, 149 synonymous, 9 deletion, 3 frame shift mutations and 17 stop-gained mutations compared to other proteins. The SARS-CoV-2 genome has 15 non-structural proteins nsp1-10 and nsp12-16 (total 16 nsps including nsp11) along with 8 auxillary protein ORF3a, ORF3b, ORFp6, ORF7a, ORF7b, ORF8b, ORF9b and ORF14. These proteins play a key role in viral amplification. Mutations in these auxiliary/accessory proteins were not found so far (Banerjee et al. 2020; Kim et al. 2020; Mercatelli and Giorgi 2020; Wu et al. 2020) . It is important to verify for and analyze these mutations to understand the pathogenicity and to improve the host immunity. SARS-CoV-2 mutational data were collected from existing literature as well as our lab reports. According to WHO, diagnosis of COVID-19 infection at appropriate time after initial observation of symptoms play a crucial role in the control of pandemic. As of now, many commercial kits are available using nasal, nasopharyngeal and saliva samples. In India, multiple kits were available using saliva swab samples including IgG/IgM antibodies by myLAB Box, gold nanoparticles-based colorimetric detection kit by Oxford Suzhou center for advanced research and gold nanoparticles coated with glucans-based colorimetric detection by Iceni Diagnostics (Amawi et al. 2020 ). Additionally, real-time PCR amplification of viral E gene assay confirmatory testing and RdRp/nsp7-8-12 gene assay, based on collection of respiratory samples from hospitalized patients is also being developed and used for the detection of COVID-19 (Corman et al. 2020) . Globally various PCRbased (single gene and multiple gene amplification, realtime based, LAMP based) and antigen-antibody interactionbased assays are available using various clinical samples. As SARS-CoV can infect all the general population in various ways, infection rate can be classified into mild, moderate and severe. Mild and moderate infections are with asymptomatic and/or few symptoms (fever, cold, dry Cough, tiredness, headache, pains, loss of smell and taste) and potentially get cured by home isolation (da Rosa et al. 2021) . In case of severe infections of COVID due to high viral titers that leads to hypoxia especially in individuals with co-morbidities like obesity, diabetes, cardiovascular and neurological diseases. There are 27 clinical manifestations and few were summarised in Table 3 Therapeutic strategies Sheahan et al. (2020) report describes the clinical protocols for the diagnosis and treatment of COVID-19, in which many therapeutic strategies to treat COVID-19 are being mentioned. The strategies predominantly include convalescent plasma therapy, circulatory and blood purification support, antiviral therapy, oxygen therapy, mechanical ventilation (invasive), immunotherapy, rescue therapy, renal replacement/transplant, and additional treatment options including usage of traditional medicines. Studies have shown that SARS-CoV-2 viral loads are significantly comparable to the disease intensity and progression (Horby et al. 2021) , which highlights the importance of having a therapeutic strategy not only to treat the symptoms of infection, but also to be able to deal with the reduction in the viral loads. Known anti-viral and other drugs including remdesiver, IFN-α, Lopinavir/ritonavir, Ribavirin, Chloroquine phosphate and hydroxychloroquine along with azithromycin and Arbidol, were used initially that were claimed to have a encouraging response in the preliminary treatment of COVID-19 (Vahey et al. 2020; Cyranoski 2020; Shen et al. 2020; Dong et al. 2020; McKee et al. 2020; Lai et al. 2020; Gautret et al. 2020) . Later many research groups and pharmaceutical giants throughout the world started researching extensively on development of more specific therapeutic strategies to curtail COVID-19 infection and spread (Alijotas et al. 2020) . Recently in India, the Drug Controller General of India approved the drug 2-Deoxy d-Glucose (2-DG), for emergency usage for moderate to severe COVID-19 patients (Verma et al. 2020) . Besides, many candidate drugs viz., baricitinib, fedratinib, and ruxolitinib, JAK-STAT signaling inhibitors were being proposed to deal with elevated levels of cytokines during the infection (Stebbing et al. 2020 ). Parallel, due to the global demand for development of a permanent cure to the problem, many vaccines, drug and immunotherapeutic candidates were being proposed which started making their way into the clinical trials, the current status of which are being summarized in Tables 4 and 5 . Moreover, vaccines are the most effective prophylactic/therapeutic strategies for the protection of global health (Cunningham et al. 2020). Since passive immunization had been successfully used to treat infectious diseases, convalescent plasma therapy was anticipated to show effective therapeutic potential in treating COVID-19 it became one of the treatment options initially (Lai et al. 2020) . Moreover, immediate By virtue of their multi-targeted and less toxic features, phytomedicines have attracted attention for prevention of many viral infections including COVID19. The increasing scientific proof of rich phytoconstituents in phytomedicine and ensuing treatment/prophylactic potentials have created remarkable confidence in the society (Girija and Sivan 2020) . This led to a rise in confidence towards alternative traditional medicine. According to WHO reports, traditional medicine (TM) which includes Indian Ayurveda, Chinese medicine, and Arabic Unani medicinal therapies that use herbs/natural products are widely and rapidly growing health systems with plenty of economic advantage. Rich local traditional/cultural adaptations in countries like Belgium (38%), China (40%), USA (42%), Australia (48%), Canada (70%), India (70%), France (75%) and Africa (80%) are leaning more towards TM. In multiple geographical areas including Asia and Latin America, people prefer to use TM due to cultural beliefs and ancient traditions. TM is not only seen in developing and underdeveloped countries but in many developed countries it is increasingly accepted and growing rapidly. Potential of Ayurveda-based rasayana botanicals, which includes Withania somnifera, Tinospora cordifolia and Asparagus racemosus, in COVID-19 treatment is being postulated (Ang et al. 2020 ) using in-silico approaches by therapeutic potential of Ayurvedic preparations viz., Sudarshana Churna, Dhanvantara Gutika and Talisadi Churna along with proper diet and self-quarantining, in a selfdetected COVID-19 case is being reported by (DU et al. 2020) . As per the Chinese and Korean guidelines, frequency of commonly used plant formulations for COVID-19 treatments is being extensively reviewed by use of traditional Chinese medicines in prevention of COVID-19 infection in healthy population and also treating the symptoms for patients at all stages of corona-viral/entero-viral infections were reported (Ren et al. 2020; Luo et al. 2020; Ni et al. 2020) . Details of the different phytotherapeutic interventions that are being proposed/recommended/already attempted until now in literature to treat corona/entero viral infections in specific are being summarized in Table 6 . From January 2020, many studies and publications on SARS CoV-2 whole genome sequences analysis and mutational analysis have been initiated and many are underway with spectacular collaborations among scientists from academia and multiple bio-pharmaceutical companies in the successful discovery and manufacture of various vaccines. According to WHO and the COVID-19 vaccine tracker, 74 vaccine candidates are being developed or under development worldwide. Among these few vaccines successfully completed 3rd phase trials and now those are in use and the data were shown in Table 7 . BNT162b2 BNT162b2 mRNA-based vaccine was developed by the Pfizer BioNtech, Fousun pharma. BioNtech is the first company to register for the FDA approval of their candidate COVID-19 vaccine. BNT162b2 is a lipid nanoparticle-based RNA vaccine (with nucleoside-modifications), encoding the SARS-CoV-2 full-length spike protein. Two proline mutations locks the spike protein confirmation in the prefusion conformation (Polack et al. 2020) . After its development and testing, the vaccine has been designated to be administered in two doses, 21 days apart. After entry into the host cell, it makes multiple copies of viral full length spike protein through immune cells. It shows 95% efficiency by encoding the viral spike protein for immune response. Total number of participants that participated in the study were 43,448 around the world (Sadoff et al. 2021) . BNT162b2 administered doses have depended on neutralizing antibodies higher against the SARS-CoV-2. The significant immunogenicity and activation of the CD8+ and CD4+ T-cells was found (Clinical Trial id: NCT04368728). mRNA-1273 mRNA-1273 COVID-19 vaccine is the first vaccine to be enrolled for clinical trials after complete SARS-CoV-2 genome sequencing and was developed by US-based start-up company, Moderna (Wang et al. 2021) . mRNA-1273 is a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine that uses/delivers prefusion stabilized spike (S) protein of SARS-CoV-2. The mRNA translates to produce SARS-CoV-2 viral spike protein (full length), thereby allowing the body to generate an immune response and retain that information in memory immune cells. Efficacy shown in study participants who received the 2 doses of vaccine with negative baseline SARS-CoV-2 status, was approximately 94% for the follow-up period of 9 weeks. The data reviewed concludes that the benefits of mRNA-1273 vaccine outweigh the known and potential risks (Wu et al. 2021) . Covaxin (BBV152) India's first indegenous COVID19 vaccine BBV152/Covaxin was developed by Bharat Biotech in collaboration with Indian Council of Medical Research and National Institute of Virology. This vaccine used SARS-CoV2 whole-virion inactivated by β-propiolactone. The strain used, NIV-2020-770 contains the Asp614Gly mutation. It showed 50% efficiency with safe and immune response in the clinical trial with recruited 25,800 participants. However, the inactivation of SARS-CoV2 by β-propiolactone was reported to cause aggregation of the viral particles leading to loss of antigenic potential. This vaccine is also effective against the UK B.1.1.7 variants and specific to neutralizing IgG antibodies. The Drug controller general of India has approved after three phase clinical trials successfully present it has huge production in India (Ella et al. 2021) . CoronaVac CoronaVac COVID-19 Vaccine developed by Sinovac Biotech Ltd. is an inactivated pathogen. The virus is inactivated by β-propiolactone and then adjuvanted with aluminum hydroxide to make the vaccine, which is generally administered on a 0/14-28-day schedule to prevent the disease. This vaccine is also potent/protects against B.1.351, a South African variant and B.1.1.7, a UK variant. The resist-ance of the variants could be neutralized by this vaccine (Tanriover et al. 2021) . As an assessment of the WHO's, the advisory group approved this vaccine for emergency use. The phase 3 clinical trials were conducted internationally on 9000 participants (clinical id: NCT04456595). BBIBP-CorV BBIBP-CorV developed by Sinopharm, it is an inactivated vaccine. Study reports revealed that the vaccine have efficiencies upto 79.3% by neutralizing the antibodies with two doses after 21 days vaccination . This vaccine works the same as coronaVac and is made based on the UK strains, and WHO advised its usage only upon emergency. The sample size for this clinical trial was 1300 (Clinical id NCT04560881). The ChAdOx1 nCoV-19 vaccine (AZD1222) was developed at Oxford University. AZD1222 contains SARS-CoV-2 structural spike protein gene delivered by In use Zhu et al. (2020) replication-deficient adenoviral vector ChAdOx1 (chimpanzee) (Voysey et al. 2021) . As per reports, this vaccine has 65% efficiency against COVID-19 after 28 days of 2 dose vaccination and has shown blood clotting issues after vaccination. Due to this reason, 12 countries across the globe rejected the use of this vaccine. After the safety community confirmed the vaccine benefits more than the risks and its non-association with high risk of blood clotting, on 31 March 2021. AstraZeneca, TGA, WHO and MHRA have issued statements for the safety use and efficiency . This vaccine worked against UK variants and induced antibodies were low with neutralisation. 32,000 participants participated in clinical trials (Clinical trial id NCT04516746). (Logunov et al. 2021) . Rare incidences of cerebral venous sinus thrombosis was observed after taking this vaccination, US had paused the administration of the vaccine while FDA, CDC and ACIP investigated the risks. On 20 April EMA approved by saying that, thrombosis is rare and common with decreased numbers of blood platelets. The total number of clinical trial participants is 43,783 and it is an effective vaccine against moderate and severe COVID-19 in the United States (Clinical id NCT04505722). CanSino Biologics using adenovirus vector, Canvidicea. Ad5-nCoV is an Ad5 vector based (E1 and E3 deleted, replication defective) vaccine expressing the full-length spike protein of COVID19 virus (Wuhan-Hu-1 strain, YP_009724390) with the tissue plasminogen activator signal peptide gene . This vaccine has an efficiency of 65% with two doses of vaccination in 21 days. In clinical trials, 40,000 participants are involved (Clinical trial id NCT04526990. After vaccination elevated IFN-α levels and T-cell response were observed. EpiVacCorona EpiVacCorona is a chemically synthesized peptide (three short fragments/epitopes of viral spike protein)-based vaccine developed by the federal budgetary and state research center of virology, Russia. These short peptides represent the immunogenic B-cell epitopes that should be recognized by the human immune system. The peptides are subsequently conjugated to a chimeric carrier protein and given as a vaccine. The vaccine showed 90% efficiency as per reports after administration of two doses in 21 days. Reports also revealed the vaccine tolerability, safety, immunogenicity against COVID-19 (Ryzhikov et al. 2021 ). The total 3000 study participants participated (Clinical id NCT04527575) in this clinical trial. Novavax is developing a vaccine called NVX-CoV2373 with a prefusion protein nanoparticles against COVID-19. This vaccine has the highest efficiency against COVID-19. This is under a third phase clinical trial and soon it will come into use. NVX-CoV2373 (Clinical trials id NCT04368988) induced immunogenicity and showed protective response against respiratory diseases (Poland et al. 2020; Cheryl et al. 2020; Shinde et al. 2021) . Another vaccine, ZyCoV-D is a plasmid based DNA Vaccine, under phase 3 clinical trials, with approval from Drug Control General of India. It exhibited an efficient immune response. Abdala (CIGB 66), a protein-based vaccine, is under phase 3 clinical trial (Yadav et al. 2020; Ward et al. 2020) . Medicago is an influenza vaccine that is under trial. When tested after 20 days, virallike particles were working against the COVID-19. Under fast track FDA approved to release vaccine for emergency use. VLA2001 is an inactivated vaccine developed with support from the UK national institute of health research. This vaccine is safer and well tolerated to neutralize antibodies in study participants (Peter et al. 2020; Cecilia et al. 2020; Smith et al. 2020; Pablo et al. 2020; Elizabeth et al. 2020; Capone et al. 2020; Richmond et al. 2021 ). In addition, there are about 60 vaccines under trials. Few vaccines are in phase-3 trials and many are in phase-1 or -2 trial shown in Table 8 . MV-014-212, PTX-COVID19-B, COVI-VAC, CORVax12, MVA-SARS-2-S, COHO4S1, Pvac, Admir SC-2f, BAC-TRL-Spike, Covax-19, DelNS1-2019-nCoV RBD -OPT1, UQ-CSLV451, VXA-CoV2-1, AdCOVID, AACOVID, ChAd-SARS-CoV-2-S, HaloVax, LineaDNA, PittCoVacc, T-COVIDTM, LNP-nCoVsaRNA, V590, and V 591 along with few unnamed vaccines that are undergoing clinical trials. (https:// www. raps. org/ news-and-artic les/ news-artic les/ 2020/3/ covid-19-vacci ne-track er). SARS-CoV-2 viral lineage analysis and review of its genetic recombination patterns shows the SARS-CoV-2 variants that pose health threats especially to the humans. This is majorly caused by crossing of genetical regions among different SARS-CoV-2 strains that can be haphazard as different recombinant strains have diverse severing points. Though many candidate vaccines, drugs and therapies are under trial stage, keeping in view the global viral mutation frequencies, it is warranted to have a multi-therapeutic approach to effectively target COVID-19 or any other possible coronavirus infection variants. There are many more potential therapeutics including phytomedicines, that can be aimed at multiple target sites of the viral infection pathways. The use of phytomedicines in these lines cannot be ignored, since phytochemicals are proven to possess multiple targeted therapeutic approaches, with no/little side effects. Moreover, phytochemicals and herbal formulations are proved to possess antiviral properties especially against human viral infections and hence their role in effectively combating the current pandemic appears significant, which also needs urgent attention. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: a comprehensive review COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics Herbal medicine and pattern identification for treating COVID-19: a rapid review of guidelines Efficacy of Tinospora cordifolia in treating SARS-CoV-2: in silico studies Selection of viral variants during persistent infection of insectivorous bat cells with Middle East respiratory syndrome coronavirus Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19 Lack of evidence for BCG vaccine protection from severe COVID-19 SARS-CoV-2 spike mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR Treatment of COVID-19: old tricks for new challenges Profile of a killer: the complex biology powering the coronavirus pandemic Clinical manifestations of COVID-19 in the general population: systematic review Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group Discovering drugs to treat coronavirus disease 2019 (COVID-19) Mini-review discussing the reliability and efficiency of COVID-19 vaccines Traditional Chinese Medicine: an effective treatment for 2019 novel coronavirus pneumonia (NCP) Complete protection of nasal and lung airways against SARS-CoV-2 challenge by antibody plus Th1 dominant N-and S-Specific T-Cell responses to subcutaneous prime and thermally-stable oral boost bivalent hAd5 vaccination in an NHP study Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Ayurvedic treatment of COVID-19/ SARS-CoV-2: a case report The species severe acute respiratory syndrome related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 Recognizing species as a new focus of virus research Dexamethasone in hospitalized patients with covid-19 Sputnik V COVID-19 vaccine candidate appears safe and effective Treating COVID-19-off-label drug use, compassionate use, and randomized clinical trials during pandemics Genome-wide identification and characterization of point mutations in the SARS-CoV-2 genome Variant analysis of SARS-CoV-2 genomes Phase 1 assessment of the safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 in human volunteers Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges Coronaviridae-Old friends, new enemy! Oral Dis The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity The reproductive number of COVID-19 is higher compared to SARS coronavirus 2021) Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia Can Chinese Medicine Be Used for Prevention of Corona Virus Disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant Mutations in SARS-CoV-2 viral RNA identified in Eastern India: possible implications for the ongoing outbreak in India and impact on viral structure and host susceptibility Candidate drugs against SARS-CoV-2 and COVID-19 Geographic and genomic distribution of SARS-CoV-2 mutations Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals Safety and immunogenicity of INO-4800 DNA vaccine againstSARS-CoV-2: a preliminary report of an openlabel, Phase 1 clinical trial COVID-19 diagnosis and management: a comprehensive review Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates Mutational analysis in international isolates and drug repurposing against SARS-CoV-2 spike protein: molecular docking and simulation approach Mutational insights into the envelope protein of SARS-CoV-2 Traditional Chinese medicine for COVID-19 treatment Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial Immunogenicity and protectivity of the peptide vaccine against SARS-CoV-2 Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19 Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV Treatment of 5 critically ill patients with COVID-19 with convalescent plasma Emerging variants of concern in SARS-CoV-2 membrane protein: a highly conserved target with potential pathological and therapeutic implications Carrim-Ganey N, Baillie V et al (2021) Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants-Withania somnifera (Ashwagandha), Tinospora cordifolia (Giloy) and Ocimum sanctum (Tulsi)-a molecular docking study Immunogenicity of a DNA vaccine candidate for COVID-19 COVID-19: combining antiviral and anti-inflammatory treatments The hallmarks of COVID-19 disease Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (Corona-Vac): interim results of a double-blind, randomised, placebocontrolled, phase 3 trial in Turkey The structure of the membrane protein of SARS-CoV-2 resembles the sugar transporter SemiSWEET Symptom profiles and progression in hospitalized and nonhospitalized patients with coronavirus disease A combinatorial approach of a polypharmacological adjuvant 2-deoxy-D-glucose with low dose radiation therapy to quell the cytokine storm in COVID-19 management Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2 Susceptibility of circulating SARS-CoV-2 variants to neutralization Phase 1 trial of a candidate recombinant viruslike particle vaccine for Covid-19 disease produced in plants Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China Serum neutralizing activity elicited by mRNA-1273 vaccine Assessment of immunogenicity and protective efficacy of ZyCoV-D DNA vaccine candidates in Rhesus macaques against SARS-CoV-2 infection Genetic cluster analysis of SARS-CoV-2 and the identification of those responsible for the major outbreaks in various countries A pneumonia outbreak associated with a new coronavirus of probable bat origin Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-inhuman trial Coronavirus vaccine tracker. The New York Times The authors declare no conflict of interest.